原始来源记录
决策级顶线结果
Enanta 报告 RSVHR 2b 期 zelicapavir 阳性 top-line 结果
RSVHR 2b 期研究达到关键次要终点，显示高危成人 RSV 患者在症状缓解速度和住院率方面均优于安慰剂，具有临床意义。这些支持 3 期试验的结果为 zelicapavir 作为该门诊人群首款有临床获益的抗病毒药物进一步开发提供依据。
关键事实
- 申报时间
- 2025年11月17日 21:15
- 事件
- 顶线结果
- 方向
- 积极
- 来源
- SEC 8-K
- 可信度
- 有来源
- 安全性
- 良好，耐受性佳
- 住院减少
- 低于安慰剂
- 症状缓解获益
- 总体2.2天，高风险3人群6.7天
来源摘录
EX-99.1 2 enta-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Enanta Pharmaceuticals Reports Financial Results for its Fiscal Fourth Quarter and Year -Ended September 30, 2025 • Announces EPS-3903, an Oral, Once-Daily STAT6 Inhibitor Development Candidate with Rapid, Continuous and Complete (>90%) In Vivo pSTAT6 Suppression and Efficacy Comparable to Dupilumab in Asthma and Atopic Dermatitis Disease Models • Announces EDP-978, an Oral, Once-Daily KIT Inhibitor Clinical Candidate with Plans to File an Investigational New Drug Application in Q1 2026 • Reported Positive Topline Data for RSVHR, a Phase 2b Study of Zelicapavir in High-Risk Adults Infected with Respiratory Syncytial Virus (RSV) • Strong Financial Position Ending Fiscal 2025 with $188.9 Million in Cash, Cash Equivalents and Market